Brief: EQL Pharma: Mandatory Offer From Fårö Capital

EQL Pharma AB

20/03/2019 07:57

March 20 (Reuters) - EQL Pharma AB  EQL.TE :
    * EQL PHARMA - INFORMATION REGARDING DISCLOSURE NOTICE AND
MANDATORY OFFER FROM FÅRÖ CAPITAL AB
    * BOARD OF DIRECTORS OF EQL PHARMA WILL NOW EVALUATE
MANDATORY
OFFER FROM FÅRÖ CAPITAL
    * FÅRÖ CAPITAL, CO CONTROLLED BY EQL PHARMA CEO, HAS
ACQUIRED
SHARES IN EQL PHARMA SO THAT LIMIT FOR MANDATORY OFFER HAS BEEN
ACHIEVED
    * AFTER ACQUISITION, FÅRÖ CAPITAL HOLDS APPROXIMATELY 30
PERCENT
OF VOTES AND CAPITAL OF EQL PHARMA
    * ACQUISITION WAS CARRIED OUT IN BLOCK POST OUTSIDE MARKET
VIA
CASH ACQUISITION AT PRICE SEK 11.35 PER EQL PHARMA SHARE
    * EQL PHARMA SHAREHOLDERS OFFERED POSSIBILITY TO TRANSFER
ALL OR
PART OF THEIR SHARES IN EQL PHARMA TO FÅRÖ CAPITAL FOR CASH
CONSIDERATION OF SEK 12.00 PER SHARE
    * ACCEPTANCE PERIOD RUNS FROM MARCH 22 TO APRIL 25

Source text for Eikon:  ID:nWkr4NBbDK 
Further company coverage:  EQL.TE 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))